Subcutaneous interferon beta 1a (IFN β 1a) has been shown to reduce relapse rates in patients with relapsing-remitting
multiple sclerosis. We report the occurrence of severe necrotizing cutaneous reactions in a 19-year-old girl. She self
injected IFN β 1a three times a week on the abdomen and both thighs. Treatment was initially well tolerated, but she
described erythematous patches and local pain at the injection sites recently. The areas on the abdomen became
violaceous with necrotic ulcers. Her therapy was changed to 0.5 mg fingolimod. The lesions began to improve and
cicatrize after several weeks with postinflammatory hyperpigmentation. Early recognition of severe local adverse
reactions and correction of the injection technique is important.
Birincil Dil | İngilizce |
---|---|
Konular | İç Hastalıkları |
Bölüm | Case Report |
Yazarlar | |
Yayımlanma Tarihi | 30 Aralık 2018 |
Gönderilme Tarihi | 6 Ekim 2017 |
Yayımlandığı Sayı | Yıl 2018 Cilt: 12 Sayı: 4 |